Reference for Chapter 53: Dermatomyositis - Rooks Textbook of Dermatology

1 Bohan A, Peter JB. Polymyositis and dermatomyositis. N Engl J Med. 1975;292:344–7, 403–7. Cross Ref link Pubmed link
2 Sontheimer RD. Would a new name hasten the acceptance of amyopathic dermatomyositis (dermatomyositis siné myositis) as a distinctive subset within the idiopathic inflammatory dermatomyopathies spectrum of clinical illness? J Am Acad Dermatol 2002;46:626–36. Cross Ref link Pubmed link
3 Taborda AL, Azevedo P, Isenberg DA. Retrospective analysis of the outcome of patients with idiopathic inflammatory myopathy: a long‐term follow‐up study. Clin Exp Rheumatol 2014;32(2):188–93. Pubmed link
4 Studynkova J, Mann H, Jarosova K, et al. A prospective, randomized, open‐label, assessor‐blind, multicenter study of efficacy and safety of combined treatment of methotrexate + glucocorticoids versus glucocorticoids alone in patients with polymyositis and dermatomyositis (prometheus trial). Ann Rheum Dis 2014;73(Suppl. 2):171. Cross Ref link
5 Lundberg IE, Forbess CJ. Mortality in idiopathic inflammatory myopathies. Clin Exp Rheumatol. 2008;26(5 Suppl. 51):S109–114. Pubmed link
6 Smoyer‐Tomic KE, Amato AA, Fernandes AW. Incidence and prevalence of idiopathic inflammatory myopathies among commercially insured, Medicare supplemental insured, and Medicaid enrolled populations: an administrative claims analysis. BMC Musculoskelet Disord 2012;13:103. Cross Ref link Pubmed link
7 Cooper GS, Stroehla BC. The epidemiology of autoimmune diseases. Autoimmun Rev. 2003;2:119–25. Cross Ref link Pubmed link
8 Oddis CV, Conte CG, Steen VD, Medsger TA. Incidence of polymyositis‐dermatomyositis: a 20‐year study of hospital diagnosed cases in Allegheny County, PA 1963–1982. J Rheumatol 1990;17(10):1329–34. Pubmed link
9 Benbassat J, Geffel D, Zlotnick A. Epidemiology of polymyositis‐dermatomyositis in Israel, 1960–76. Isr J Med Sci 1980;16(3):197–200. Pubmed link
10 Bernatsky S, Joseph L, Pineau CA, et al. Estimating the prevalence of polymyositis and dermatomyositis from administrative data: age, sex and regional differences. Ann Rheum Dis 2009;68(7):1192–6. Cross Ref link Pubmed link
11 Hengstman GJ, van Venrooij WJ, Vencovsky J, Moutsopoulos HM, van Engelen BG. The relative prevalence of dermatomyositis and polymyositis in Europe exhibits a latitudinal gradient. Ann Rheum Dis. 2000;59(2):141–2. Cross Ref link Pubmed link
12 Love LA, Weinberg CR, McConnaughey DR, et al. Ultraviolet radiation intensity predicts the relative distribution of dermatomyositis and anti‐Mi‐2 autoantibodies in women. Arthritis Rheum 2009;60(8):2499–504. Cross Ref link Pubmed link
13 Bohan A, Peter JB, Bowman RL, Pearson CM. Computer‐assisted analysis of 153 patients with polymyositis and dermatomyositis. Medicine (Baltimore) 1977;56(4):255–86. Cross Ref link Pubmed link
14 Dobloug C, Garen T, Bitter H, et al. Prevalence and clinical characteristics of adult polymyositis and dermatomyositis; data from a large and unselected Norwegian cohort. Ann Rheum Dis 2014;1551–6. Pubmed link
15 Symmons DP, Sills JA, Davis SM. The incidence of juvenile dermatomyositis: results from a nation‐wide study. Br J Rheumatol 1995;34(8):732–6. Cross Ref link Pubmed link
16 Hill CL, Zhang Y, Sigurgeirsson B, et al. Frequency of specific cancer types in dermatomyositis and polymyositis: a population‐based study. Lancet 2001;357:96–100. Cross Ref link Pubmed link
17 Leow YH, Goh CL. Malignancy in adult dermatomyositis. Int J Dermatol 1997;36(12):904–7. Cross Ref link Pubmed link
18 Goh CL, Rajan VS. Dermatomyositis in a skin clinic. Ann Acad Med Singapore 1983;12(1):6–12. Pubmed link
19 Henriksson KG, Lindvall B. Polymyositis and dermatomyositis 1990 – diagnosis, treatment and prognosis. Prog Neurobiol 1990;35(3):181–93. Cross Ref link Pubmed link
20 Buchbinder R, Forbes A, Hall S, Dennett X, Giles G. Incidence of malignant disease in biopsy‐proven inflammatory myopathy. A population‐based cohort study. Ann Intern Med 2001;134(12):1087–95. Cross Ref link Pubmed link
21 Ponyi A, Borgulya G, Constantin T, Váncsa A, Gergely L, Dankó K. Functional outcome and quality of life in adult patients with idiopathic inflammatory myositis. Rheumatology (Oxford) 2005;44(1):83–8. Cross Ref link Pubmed link
22 András C, Ponyi A, Constantin T, et al. Dermatomyositis and polymyositis associated with malignancy: a 21‐year retrospective study. J Rheumatol 2008;35(3):438–44. Pubmed link
23 Chinoy H, Fertig N, Oddis CV, Ollier WE, Cooper RG. The diagnostic utility of myositis autoantibody testing for predicting the risk of cancer‐associated myositis. Ann Rheum Dis 2007;66(10):1345–9. Cross Ref link Pubmed link
24 Fiorentino DF, Chung LS, Christopher‐Stine L, et al. Most patients with cancer‐associated dermatomyositis have antibodies to nuclear matrix protein NXP‐2 or transcription intermediary factor 1γ. Arthritis Rheum 2013;65(11):2954–62. Cross Ref link Pubmed link
25 Chen YJ, Wu CY, Huang YL, Wang CB, Shen JL, Chang YT. Cancer risks of dermatomyositis and polymyositis: a nationwide cohort study in Taiwan. Arthritis Res Ther 2010;12(2):R70. Cross Ref link Pubmed link
26 Kissel JT, Mendell JR, Rammohan KW. Microvascular deposition of complement membrane attack complex in dermatomyositis. N Engl J Med 1986;314:329–34. Cross Ref link Pubmed link
27 Kissel JT, Halterman RK, Rammohan KW, Mendell JR. The relationship of complement‐mediated microvasculopathy to the histologic features and clinical duration of disease in dermatomyositis. Arch Neurol 1991;48:26–30. Cross Ref link Pubmed link
28 McDouall RM, Dunn MJ, Dubowitz V. Expression of class I and class II MHC antigens in neuromuscular diseases. J Neurol Sci 1989;89(2–3):213–26. Cross Ref link Pubmed link
29 Hathaway PW, Engel WK, Zellweger H. Experimental myopathy after microarterial embolization; comparison with childhood x‐linked pseudohypertrophic muscular dystrophy. Arch Neurol 1970;22(4):365–78. Cross Ref link Pubmed link
30 Karpati G, Carpenter S, Melmed C, Eisen AA. Experimental ischemic myopathy. J Neurol Sci 1974;23(1):129–61. Cross Ref link Pubmed link
31 Greenberg SA, Pinkus JL, Pinkus GS, et al. Interferon‐alpha/beta‐mediated innate immune mechanisms in dermatomyositis. Ann Neurol 2005;57(5):664–78. Cross Ref link Pubmed link
32 Ghirardello A, Bassi N, Palma L, et al. Autoantibodies in polymyositis and dermatomyositis. Curr Rheumatol Rep 2013;15(6):335. Cross Ref link Pubmed link
33 Stone KB, Oddis CV, Fertig N, et al. Anti‐Jo‐1 antibody levels correlate with disease activity in idiopathic inflammatory myopathy. Arthritis Rheum 2007;56(9):3125–31. Cross Ref link Pubmed link
34 Muro Y, Sugiura K, Hoshino K, Akiyama M. Disappearance of anti‐MDA‐5 autoantibodies in clinically amyopathic DM/interstitial lung disease during disease remission. Rheumatology (Oxford) 2012;51(5):800–4. Cross Ref link Pubmed link
35 Howard OM, Dong HF, Yang D, et al. Histidyl‐tRNA synthetase and asparaginyl‐tRNA synthetase, autoantigens in myositis, activate chemokine receptors on T lymphocytes and immature dendritic cells. J Exp Med 2002;196:781–91. Cross Ref link Pubmed link
36 Levine SM, Raben N, Xie D, et al. Novel conformation of histidyl‐transfer RNA synthetase in the lung: the target tissue in Jo‐1 autoantibody‐associated myositis. Arthritis Rheum 2007;56(8):2729–39. Cross Ref link Pubmed link
37 Casciola‐Rosen L, Nagaraju K, Plotz P, et al. Enhanced autoantigen expression in regenerating muscle cells in idiopathic inflammatory myopathy. J Exp Med 2005;201(4):591–601. Cross Ref link Pubmed link
38 Walsh RJ, Kong SW, Yao Y, et al. Type I interferon‐inducible gene expression in blood is present and reflects disease activity in dermatomyositis and polymyositis. Arthritis Rheum 2007;56(11):3784–92. Cross Ref link Pubmed link
39 Eloranta ML, Barbasso Helmers S, Ulfgren AK, Rönnblom L, Alm GV, Lundberg IE. A possible mechanism for endogenous activation of the type I interferon system in myositis patients with anti‐Jo‐1 or anti‐Ro 52/anti‐Ro 60 autoantibodies. Arthritis Rheum 2007;56(9):3112–24. Cross Ref link Pubmed link
40 Suber TL, Casciola‐Rosen L, Rosen A. Mechanisms of disease: autoantigens as clues to the pathogenesis of myositis. Nat Clin Pract Rheumatol 2008;4(4):201–9. Cross Ref link Pubmed link
41 Sontheimer RD. Lichenoid tissue reaction/interface dermatitis: clinical and histological perspectives. J Invest Dermatol 2009;129(5):1088–99. Cross Ref link Pubmed link
42 Callen JP. Dermatomyositis. Lancet 2000;355(9197):53–7. Cross Ref link Pubmed link
43 Hundley JL, Carroll CL, Lang W, et al. Cutaneous symptoms of dermatomyositis significantly impact patients' quality of life. J Am Acad Dermatol 2006;54:217–20. Cross Ref link Pubmed link
44 Cheong WK, Hughes GR, Norris PG, Hawk JL. Cutaneous photosensitivity in dermatomyositis. Br J Dermatol 1994;131(2):205–8. Cross Ref link Pubmed link
45 Okiyama N, Kohsaka H, Ueda N, et al. Seborrheic area erythema as a common skin manifestation in Japanese patients with dermatomyositis. Dermatology 2008;217(4):374–7. Cross Ref link Pubmed link
46 Kasteler JS, Callen JP. Scalp involvement in dermatomyositis. Often overlooked or misdiagnosed. JAMA 1994;272(24):1939–41. Cross Ref link Pubmed link
47 Hasegawa M. Dermoscopy findings of nail fold capillaries in connective tissue diseases. J Dermatol 2011;38(1):66–70. Cross Ref link Pubmed link
48 Quinter SD, Chiu YE, Lyon VB, Holland KE, Ruggeri SY, Drolet BA. Inverse Gottron's papules: an unusual cutaneous manifestation of juvenile dermatomyositis. Pediatr Dermatol 2012;29(5):641–4. Cross Ref link Pubmed link
49 Nishigori K, Yamamoto T, Yokozeki H. Vesiculo‐bullous dermatomyositis: report of three cases. Dermatol Online J 2009;15(4):6. Pubmed link
50 Fiorentino D, Chung L, Zwerner J, Rosen A, Casciola‐Rosen L. The mucocutaneous and systemic phenotype of dermatomyositis patients with antibodies to MDA5 (CADM‐140): a retrospective study. J Am Acad Dermatol 2011;65(1):25–34. Cross Ref link Pubmed link
51 Nousari HC, Ha VT, Laman SD, Provost TT, Tausk FA. “Centripetal flagellate erythema”: a cutaneous manifestation associated with dermatomyositis. J Rheumatol 1999;26(3):692–5. Pubmed link
52 Yamamoto T, Nishioka K. Flagellate erythema. Int J Dermatol 2006;45(5):627–31. Cross Ref link Pubmed link
53 Sato Y, Teraki Y, Izaki S, Amano K. Clinical characterization of dermatomyositis associated with mechanic's hands. J Dermatol 2012;39(12):1093–5. Cross Ref link Pubmed link
54 Valenzuela A, Chung L, Casciola‐Rosen L, Fiorentino D. Identification of clinical features and autoantibodies associated with calcinosis in dermatomyositis. JAMA Dermatol 2014;150(7):724–9. Cross Ref link Pubmed link
55 Solans R, Cortes J, Selva A, et al. Panniculitis: a cutaneous manifestation of dermatomyositis. J Am Acad Dermatol 2002;46:S148–50. Cross Ref link Pubmed link
56 Sultan SM. Clinical assessment in adult onset idiopathic inflammatory myopathy. Curr Opin Rheumatol 2004;16(6):668–72. Cross Ref link Pubmed link
57 Rider LG, Koziol D, Giannini EH, et al. Validation of manual muscle testing and a subset of eight muscles for adult and juvenile idiopathic inflammatory myopathies. Arthritis Care Res (Hoboken) 2010;62(4):465–72. Cross Ref link Pubmed link
58 Alexanderson H, Broman L, Tollbäck A, Josefson A, Lundberg IE, Stenström CH. Functional index‐2: validity and reliability of a disease‐specific measure of impairment in patients with polymyositis and dermatomyositis. Arthritis Rheum 2006;55(1):114–22. Cross Ref link Pubmed link
59 Dankó K, Ponyi A, Constantin T, Borgulya G, Szegedi G. Long‐term survival of patients with idiopathic inflammatory myopathies according to clinical features: a longitudinal study of 162 cases. Medicine (Baltimore) 2004;83(1):35–42. Cross Ref link Pubmed link
60 Marie I, Hachulla E, Chérin P, et al. Interstitial lung disease in polymyositis and dermatomyositis. Arthritis Rheum 2002;47(6):614–22. Cross Ref link Pubmed link
61 Chen YJ, Wu CY, Shen JL. Predicting factors of interstitial lung disease in dermatomyositis and polymyositis. Acta Derm Venereol 2007;87(1):33–8. Cross Ref link Pubmed link
62 Kang EH, Lee EB, Shin KC, et al. Interstitial lung disease in patients with polymyositis, dermatomyositis and amyopathic dermatomyositis. Rheumatology (Oxford) 2005;44:1282–6. Cross Ref link Pubmed link
63 Selva‐O'Callaghan A, Labrador‐Horrillo M, Muñoz‐Gall X, et al. Polymyositis/dermatomyositis‐associated lung disease: analysis of a series of 81 patients. Lupus 2005;14(7):534–42. Cross Ref link Pubmed link
64 Chua F, Higton AM, Colebatch AN, et al. Idiopathic inflammatory myositis‐associated interstitial lung disease: ethnicity differences and lung function trends in a British cohort. Rheumatology (Oxford) 2012;51(10):1870–6. Cross Ref link Pubmed link
65 Kiely PD, Chua F. Interstitial lung disease in inflammatory myopathies: clinical phenotypes and prognosis. Curr Rheumatol Rep 2013;15(9):359. Cross Ref link Pubmed link
66 Gunawardena H, Betteridge ZE, McHugh NJ. Myositis‐specific autoantibodies: their clinical and pathogenic significance in disease expression. Rheumatology (Oxford) 2009;48:607–12. Cross Ref link Pubmed link
67 Marie I, Hatron PY, Dominique S, et al. Short‐term and long‐term outcome of anti‐Jo1‐positive patients with anti‐Ro52 antibody. Semin Arthritis Rheum 2012;41(6):890–9. Cross Ref link Pubmed link
68 Hervier B, Devilliers H, Stanciu R, et al. Hierarchical cluster and survival analyses of antisynthetase syndrome: phenotype and outcome are correlated with anti‐tRNA synthetase antibody specificity. Autoimmun Rev 2012;12:210–17. Cross Ref link Pubmed link
69 Tugnet N, Rees DH. Calcinosis in juvenile dermatomyositis. Postgrad Med J 2010;86(1018):510. Cross Ref link Pubmed link
70 Huemer C, Kitson H, Malleson PN, et al. Lipodystrophy in patients with juvenile dermatomyositis – evaluation of clinical and metabolic abnormalities. J Rheumatol 2001;28(3):610–15. Pubmed link
71 Shah M, Mamyrova G, Targoff IN, et al. The clinical phenotypes of the juvenile idiopathic inflammatory myopathies. Medicine (Baltimore) 2013;92(1):25–41. Cross Ref link Pubmed link
72 Gunawardena H, Wedderburn LR, North J, et al. Clinical associations of autoantibodies to a p155/140 kDa doublet protein in juvenile dermatomyositis. Rheumatology (Oxford) 2008;47(3):324–8. Cross Ref link Pubmed link
73 Neri R, Barsotti S, Simone B, et al. Cancer‐associated myositis: a 35‐year retrospective study of a monocentric cohort. Rheumatol Int 2014;34(4):565–9. Cross Ref link Pubmed link
74 Cao H, Pan M, Kang Y, et al. Clinical manifestations of dermatomyositis and clinically amyopathic dermatomyositis patients with positive expression of anti‐melanoma differentiation‐associated gene 5 antibody. Arthritis Care Res (Hoboken) 2012;64:1602–10. Cross Ref link Pubmed link
75 Seidler AM, Gottlieb AB. Dermatomyositis induced by drug therapy: a review of case reports. J Am Acad Dermatol 2008;59:872–80. Cross Ref link Pubmed link
76 Daoud MS, Gibson LE, Pittelkow MR. Hydroxyurea dermopathy: a unique lichenoid eruption complicating long‐term therapy with hydroxyurea. J Am Acad Dermatol 1997;36(2 Pt 1):178–82. Cross Ref link Pubmed link
77 Carroll CL, Lang W, Snively B, Feldman SR, Callen J, Jorizzo JL. Development and validation of the Dermatomyositis Skin Severity Index. Br J Dermatol 2008;158(2):345–50. Cross Ref link Pubmed link
78 Isenberg DA, Allen E, Farewell V, et al. International consensus outcome measures for patients with idiopathic inflammatory myopathies. Development and initial validation of myositis activity and damage indices in patients with adult onset disease. Rheumatology (Oxford) 2004;43(1):49–54. Cross Ref link Pubmed link
79 Tisseverasinghe A, Bernatsky S, Pineau CA. Arterial events in persons with dermatomyositis and polymyositis. J Rheumatol 2009;36(9):1943–6. Cross Ref link Pubmed link
80 Zöller B, Li X, Sundquist J, Sundquist K. Risk of subsequent coronary heart disease in patients hospitalized for immune‐mediated diseases: a nationwide follow‐up study from Sweden. PLOS One 2012;7(3):e33442. Cross Ref link Pubmed link
81 Bronner IM, van der Meulen MF, de Visser M, et al. Long‐term outcome in polymyositis and dermatomyositis. Ann Rheum Dis 2006;65:1456–61. Cross Ref link Pubmed link
82 Reichlin M, Arnett FC. Multiplicity of antibodies in myositis sera. Arthritis Rheum 1984;27(10):1150–6. Cross Ref link Pubmed link
83 Rutjes SA, Vree Egberts WT, Jongen P, Van Den Hoogen F, Pruijn GJ, Van Venrooij WJ. Anti‐Ro52 antibodies frequently co‐occur with anti‐Jo‐1 antibodies in sera from patients with idiopathic inflammatory myopathy. Clin Exp Immunol 1997;109(1):32–40. Cross Ref link Pubmed link
84 Tansley S, Gunawardena H. The evolving spectrum of polymyositis and dermatomyositis – moving towards clinicoserological syndromes: a critical review. Clin Rev Allergy Immunol 2014;47(3):264–73. Cross Ref link Pubmed link
85 Sato S, Hirakata M, Kuwana M, et al. Autoantibodies to a 140‐kd polypeptide, CADM‐140, in Japanese patients with clinically amyopathic dermatomyositis. Arthritis Rheum 2005;52(5):1571–6. Cross Ref link Pubmed link
86 Nakashima R, Imura Y, Kobayashi S, et al. The RIG‐I‐like receptor IFIH1/MDA5 is a dermatomyositis‐specific autoantigen identified by the anti‐CADM‐140 antibody. Rheumatology (Oxford) 2010;49(3):433–40. Cross Ref link Pubmed link
87 Chaisson NF, Paik J, Orbai AM, et al. A novel dermato‐pulmonary syndrome associated with MDA‐5 antibodies: report of 2 cases and review of the literature. Medicine (Baltimore) 2012;91(4):220–8. Cross Ref link Pubmed link
88 Kaji K, Fujimoto M, Hasegawa M, et al. Identification of a novel autoantibody reactive with 155 and 140 kDa nuclear proteins in patients with dermatomyositis: an association with malignancy. Rheumatology (Oxford) 2007;46(1):25–8. Cross Ref link Pubmed link
89 Gunawardena H, Wedderburn LR, Chinoy H, et al. Autoantibodies to a 140‐kd protein in juvenile dermatomyositis are associated with calcinosis. Arthritis Rheum 2009;60(6):1807–14. Cross Ref link Pubmed link
90 Targoff IN, Reichlin M. The association between Mi‐2 antibodies and dermatomyositis. Arthritis Rheum 1985;28(7):796–803. Cross Ref link Pubmed link
91 Betteridge ZE, Gunawardena H, Chinoy H, et al. Clinical and human leucocyte antigen class II haplotype associations of autoantibodies to small ubiquitin‐like modifier enzyme, a dermatomyositis‐specific autoantigen target, in UK Caucasian adult‐onset myositis. Ann Rheum Dis 2009;68(10):1621–5. Cross Ref link Pubmed link
92 Streib EW, Wilbourn AJ, Mitsumoto H. Spontaneous electrical muscle fiber activity in polymyositis and dermatomyositis. Muscle Nerve 1979;2(1):14–18. Cross Ref link Pubmed link
93 Gordon PA, Winer JB, Hoogendijk JE, Choy EH. Immunosuppressant and immunomodulatory treatment for dermatomyositis and polymyositis. Cochrane Database Syst Rev 2012;Issue 8:CD003643. Pubmed link
94 Dalakas MC, Illa I, Dambrosia JM, et al. A controlled trial of high‐dose intravenous immune globulin infusions as treatment for dermatomyositis. N Engl J Med 1993;329:1993–2000. Cross Ref link Pubmed link
95 Femia AN, Eastham AB, Lam C, Merola JF, Qureshi AA, Vleugels RA. Intravenous immunoglobulin for refractory cutaneous dermatomyositis: a retrospective analysis from an academic medical center. J Am Acad Dermatol 2013;69(4):654–7. Cross Ref link Pubmed link
96 Kampylafka EI, Kosmidis ML, Panagiotakos DB, Dalakas M, Moutsopoulos HM, Tzioufas AG. The effect of intravenous immunoglobulin (IVIG) treatment on patients with dermatomyositis: a 4‐year follow‐up study. Clin Exp Rheumatol 2012;30(3):397–401. Pubmed link
97 Chung L, Genovese MC, Fiorentino DF. A pilot trial of rituximab in the treatment of patients with dermatomyositis. Arch Dermatol 2007;143(6):763–7. Cross Ref link Pubmed link
98 Oddis CV, Reed AM, Aggarwal R, et al. Rituximab in the treatment of refractory adult and juvenile dermatomyositis and adult polymyositis: a randomized, placebo‐phase trial. Arthritis Rheum 2013;65(2):314–24. Cross Ref link Pubmed link
99 Aggarwal R, Bandos A, Reed AM, et al. Predictors of clinical improvement in rituximab‐treated refractory adult and juvenile dermatomyositis and adult polymyositis. Arthritis Rheumatol 2014;66(3):740–9. Cross Ref link Pubmed link
100 Hollar CB, Jorizzo JL. Topical tacrolimus 0.1% ointment for refractory skin disease in dermatomyositis: a pilot study. J Dermatolog Treat 2004;15(1):35–9. Cross Ref link Pubmed link
101 Ang GC, Werth VP. Combination antimalarials in the treatment of cutaneous dermatomyositis: a retrospective study. Arch Dermatol 2005;141(7):855–9. Pubmed link
102 Fendler C, Braun J. Use of methotrexate in inflammatory myopathies. Clin Exp Rheumatol 2010;28:S164–7. Pubmed link

Log in to Rooks online